Bionano genomics news.

News. Press Releases. Research Reports. ... Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2023 Earnings Call Transcript November 8, 2023 Bionano Genomics, Inc. misses on earnings expectations. Reported ... SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families. The study authors conducted a comprehensive analysis of samples from ...We would like to show you a description here but the site won’t allow us.Sep 23, 2022 · SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories’ first OGM-based laboratory developed test (LDT).

Jun 12, 2023 · Submissions focused on a variety of applications including genetic disease, cancer, reproductive health, cell and gene therapy, and plant and animal research. SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the 2023 winners of its Innovator Research Grant program, including grand prize winner Dr ... Automate Data Display for Powerful Insights. VIA software amplifies the story of your data by automatically generating powerful visualizations for enhanced variant contextualization across multiple variant types happening in the same genomic region. VIA allows you to drill down to single chromosome, gene, and nucleotide levels for deeper analysis.

Oct 11, 2023 · SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, a...

Publication demonstrates that Saphyr can be powerful and easy to use for solid tumor analysis in cancer research and clinical testing. SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced the publication of a method for using optical genome mapping (OGM) to identify structural variants (SVs) that drive cancer in a wide variety of solid tumor samples.SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, a...Company Contact: Erik Holmlin, CEO. Bionano Genomics, Inc. +1 (858) 888-7610. [email protected]. Investor Relations: +1 (858) 888-7625. [email protected]. Three peer-reviewed publications ...

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from researchers...

Get the latest Bionano Genomics, Inc. (BNGO) stock news and headlines to help you in your trading and investing decisions.

Sep 30, 2022 · Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended Business Updates Since the End of Q3 2023 Q3 2023 Highlights 6,176 nanochannel array flowcells sold during the third quarter Initiated early access program for Stratys™ system , which are ongoing, $1,863.22 Latest news about Bionano Genomics, Inc. North American Morning Briefing : Caution -2- Nov. 14: DJ Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023 Nov. 08: CI Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 08: CI Bionano Genomics, …Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. GlobeNewswire.Mar 1, 2022 · As a provider of optical genome mapping systems, software, and testing and laboratory services, we believe that Bionano has transformed from an instrument company into a global genomics company focused on elevating the health and wellness of all people with a wide array of compelling solutions for genome analysis,” commented Erik Holmlin, PhD ... Pharma, BioPharma. Bionano frames $90M BioDiscovery buy as way to expand genomics analysis Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal.

Headline. After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO) finance.yahoo.com - November 17 at 2:20 PM. Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Ascendis Pharma (ASND) markets.businessinsider.com - November 16 at 11:51 PM.Bionano Genomics sees Q3 net loss widen 53% but beats on the top line SA News Thu, Nov. 03, 2022 Bionano Genomics net loss of $31.81M, revenue of …Aug 1, 2023 · SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023. Bionano Genomics has an overall rating of 3.2 out of 5, based on over 48 reviews left anonymously by employees. 55% of employees would recommend working …Bionano Genomics (NASDAQ:BNGO) effected a 1-for-10 reverse stock split and announced that it will publish quarterly earnings on Aug. 9. Shares opened this morning at $4.73 each, a market ...

7 Agu 2023 ... Bionano Genomics (NASDAQ: BNGO) stock will jump 1000% at the open this morning. BNGO stock rising 10x is not, sadly, to make up for the ...

GuruFocus Research November 8, 2023 at 6:19 PM · 4 min read Bionano Genomics Inc ( NASDAQ:BNGO) sees a 29% increase in Q3 2023 revenue, reaching …Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform ...12 Okt 2021 ... Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal. While both companies provide genomics ...SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to …The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioNano Genomics with a $2.67 average price target, which is a 281.43% upside from current levels.SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for solid tumor and hematological malignancy cancer research, including scientific …Saphyr®, Bionano's third-generation optical mapping solution, provides what's missing in genome research – rapid, high-throughput, long-range genome mapping ...

SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families.The study authors conducted a comprehensive analysis of samples from …

Mar 9, 2023 · Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.

SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families.The study authors conducted a comprehensive analysis of samples from …Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.11 per share a year ago.SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.Visualize multiple tracks of genomic data for the at-a-glance context of variant calls. NₓClinical offers multi-platform integration by: Combining current and historical molecular data from array and sequencing for sample continuity. Comparing and contrasting outputs from multiple technologies to understand the underlying biology.News Release Details « Back. Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies. Feb 22, 2023 | PDF Version. ... About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers …The company reported a 29% increase in Q3 2023 revenue compared to the same period in the previous year, reaching $9.3 million. The growth in revenue can be attributed to the continued expansion of Bionano’s installed base of Saphyr systems, which grew by 39% year-over-year. As of September 30, 2023, the company had a total of 301 …Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. GlobeNewswire. Bionano Genomics, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.75. Operator: Good day, and welcome to the Bionano’s Third Quarter 2023 Earnings Conference ...Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing Jan 19 Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Bionano Genomics: PB2245: A combination of exome sequencing and optical genome mapping unveils a dual molecular diagnosis in a case with an unknown neurodevelopmental disorder Acharya A. Columbia University: PB2261: B-allele frequency-based approach to detecting absence of heterozygosity using optical genome mapping …Welcome to the Bionano Second Quarter 2023 Financial Results Conference Call. Leading the call today is Dr. Erik Holmlin, CEO of Bionano. He's joined by Chris Stewart, CFO of Bionano. After market ...The market for genomics products and services is significant, expected to grow at a CAGR of 10.2% from 2017-2022, reaching $23.9 billion by 2022. Bionano is targeting two types of end users. First ...About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.Instagram:https://instagram. how to invest in block chainstock bhow much is a quarter worth from 1776tsls etf stock Get the latest BioNano Genomics Inc (BNGO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Nov 27, 2023 · The BioNano Genomics stock price fell by -7.27% on the last day (Monday, 27th Nov 2023) from $1.65 to $1.53. During the last trading day the stock fluctuated 10.07% from a day low at $1.49 to a day high of $1.64. The price has fallen in 5 of the last 10 days but is still up by 17.69% over the past 2 weeks. Volume has increased on the last day ... reputable online gold buyersinstant debit card bank account Aug 4, 2023 · SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ... best dental plan for braces Jul 6, 2021 · About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business ... View the real-time Bionano Genomics Inc (NASDAQ BNGO) share price and assess historical data, charts, technical analysis and the share chat forum. Download the App. ... Bionano Genomics News & Analysis. BioNano Genomics, Inc. Prices $80M Financing; Reports Prelim Q3; Implements Streamlined Operational Plan . Bionano …